Handelsbanken Fonder AB Has $1.34 Million Stock Position in Roivant Sciences Ltd. (NASDAQ:ROIV)

Handelsbanken Fonder AB lowered its stake in Roivant Sciences Ltd. (NASDAQ:ROIV) by 40.9% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 113,109 shares of the company’s stock after selling 78,300 shares during the quarter. Handelsbanken Fonder AB’s holdings in Roivant Sciences were worth $1,338,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also recently bought and sold shares of the stock. Gladius Capital Management LP purchased a new position in shares of Roivant Sciences in the third quarter worth approximately $35,000. US Bancorp DE boosted its stake in Roivant Sciences by 146.5% in the 3rd quarter. US Bancorp DE now owns 3,278 shares of the company’s stock worth $38,000 after purchasing an additional 1,948 shares during the period. GAMMA Investing LLC grew its position in Roivant Sciences by 57.0% during the 4th quarter. GAMMA Investing LLC now owns 3,548 shares of the company’s stock worth $42,000 after purchasing an additional 1,288 shares in the last quarter. Quarry LP raised its stake in Roivant Sciences by 50.0% during the 3rd quarter. Quarry LP now owns 7,500 shares of the company’s stock valued at $87,000 after purchasing an additional 2,500 shares during the period. Finally, Blue Trust Inc. lifted its holdings in shares of Roivant Sciences by 550.1% in the fourth quarter. Blue Trust Inc. now owns 7,879 shares of the company’s stock valued at $91,000 after purchasing an additional 6,667 shares in the last quarter. Institutional investors and hedge funds own 64.76% of the company’s stock.

Roivant Sciences Trading Up 1.0 %

Shares of NASDAQ:ROIV opened at $10.60 on Thursday. The business has a fifty day simple moving average of $11.14 and a 200 day simple moving average of $11.60. Roivant Sciences Ltd. has a 1 year low of $9.76 and a 1 year high of $13.06. The firm has a market cap of $7.56 billion, a price-to-earnings ratio of -70.66 and a beta of 1.25.

Roivant Sciences (NASDAQ:ROIV) last announced its quarterly earnings results on Monday, February 10th. The company reported ($0.20) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.24) by $0.04. Roivant Sciences had a negative return on equity of 14.05% and a negative net margin of 119.54%. On average, sell-side analysts forecast that Roivant Sciences Ltd. will post -0.92 EPS for the current year.

Insiders Place Their Bets

In other news, COO Eric Venker sold 100,000 shares of the company’s stock in a transaction dated Thursday, February 20th. The stock was sold at an average price of $10.65, for a total transaction of $1,065,000.00. Following the completion of the sale, the chief operating officer now owns 896,869 shares in the company, valued at approximately $9,551,654.85. This represents a 10.03 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CAO Rakhi Kumar sold 227,500 shares of the firm’s stock in a transaction that occurred on Thursday, February 13th. The shares were sold at an average price of $10.43, for a total value of $2,372,825.00. Following the completion of the transaction, the chief accounting officer now directly owns 163,264 shares in the company, valued at $1,702,843.52. The trade was a 58.22 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 2,388,170 shares of company stock valued at $27,612,299 over the last ninety days. Corporate insiders own 7.90% of the company’s stock.

Wall Street Analyst Weigh In

ROIV has been the topic of a number of research analyst reports. Cantor Fitzgerald upgraded Roivant Sciences to a “strong-buy” rating in a report on Thursday, January 30th. HC Wainwright reaffirmed a “buy” rating and set a $18.00 target price on shares of Roivant Sciences in a research note on Tuesday, February 11th. One equities research analyst has rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, Roivant Sciences has an average rating of “Buy” and a consensus price target of $18.08.

Roivant Sciences Company Profile

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.